2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice …
FLJ Visseren, F Mach, YM Smulders… - European heart …, 2021 - academic.oup.com
Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of …
Aims The expression of GADD153 (growth arrest and DNA damage-inducible gene 153), an
apoptosis-regulated gene, increases during endoplasmic reticulum (ER) stress. How …
apoptosis-regulated gene, increases during endoplasmic reticulum (ER) stress. How …
2020 International Society of Hypertension global hypertension practice guidelines
In the Guidelines, differentiation between optimal and essential standards were not always
possible, and were made in sections where it was most practical and sensible. The …
possible, and were made in sections where it was most practical and sensible. The …
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
[HTML][HTML] Phase 2 trial of baxdrostat for treatment-resistant hypertension
MW Freeman, YD Halvorsen, W Marshall… - … England Journal of …, 2023 - Mass Medical Soc
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …
pharmacologic target for the treatment of hypertension for several decades. Selective …
Brazilian guidelines of hypertension–2020
SciELO - Brasil - Diretrizes Brasileiras de Hipertensão Arterial – 2020 Diretrizes Brasileiras de
Hipertensão Arterial – 2020 Acessibilidade / Reportar erro Brasil Lista alfabética de periódicos …
Hipertensão Arterial – 2020 Acessibilidade / Reportar erro Brasil Lista alfabética de periódicos …
Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children
DM Rabi, KA McBrien, R Sapir-Pichhadze… - Canadian Journal of …, 2020 - Elsevier
Hypertension Canada's 2020 guidelines for the prevention, diagnosis, risk assessment, and
treatment of hypertension in adults and children provide comprehensive, evidence-based …
treatment of hypertension in adults and children provide comprehensive, evidence-based …
The unrecognized prevalence of primary aldosteronism: a cross-sectional study
JM Brown, M Siddiqui, DA Calhoun… - Annals of Internal …, 2020 - acpjournals.org
Background: Primary aldosteronism is a nonsuppressible renin-independent aldosterone
production that causes hypertension and cardiovascular disease. Objective: To characterize …
production that causes hypertension and cardiovascular disease. Objective: To characterize …
Obesity, kidney dysfunction and hypertension: mechanistic links
Excessive adiposity raises blood pressure and accounts for 65–75% of primary
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …
hypertension, which is a major driver of cardiovascular and kidney diseases. In obesity …